Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol.

ABSTRACT:

Background

Warfarin and similar vitamin K antagonists have been the standard therapy for patients with mechanical or biological valve prosthesis and atrial fibrillation (AF). Even with the appropriate use of therapy, some studies have reported that there is a high incidence of thromboembolic events, 1%-4% per year. Furthermore, a bleeding risk is significant, ranging from 2% to 9% per year, according to some studies.

Objective

The objective of our study was to examine the effect of dabigatran etexilate versus dose-adjusted warfarin for the prevention of intracardiac thrombus in persistent or permanent AF at least 3 months after aortic and/or mitral bioprosthesis replacement.

Methods

Dabigatran versus warfarin after bioprosthesis valve replacement for the management of

SUBMITTER: Duraes AR 

PROVIDER: S-EPMC4004148 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature